New research reveals that the urgency of combating Covid-19 drove closer collaboration between biopharma and government.
Covid-19 forced governments and biopharma companies to work together more than ever before, and at unprecedented speed, to approve products for the public good.
From rapidly accelerated development and manufacturing to improved public-private sector collaboration, the impact of the pandemic on the biopharma sector has been nothing short of phenomenal.
Video: Making policy work for the biopharma industry
Video: Biopharma reaches for homegrown talent
Video: Biopharma R&D needs more collaboration
Video: Shifting biopharma’s manufacturing into the fast lane
Video: Global or local? Biopharma's supply chain challenge